Clinical trials
Advanced Gastric Adenocarcinoma clinical trials
Below are recruiting advanced gastric adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 227 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06945718Recruiting
Green dye test for gastric cancer surgery
This trial tests whether a green dye called indocyanine green can help surgeons find and remove more lymph nodes during laparoscopic surgery for advanced stomach cancer. It may improve the chances of removing all cancer.
Fuzhou, FujianAges 18–75 - NCT07023315RecruitingPhase 3
Study of cadonilimab plus SOX before and after surgery for stomach cancer
This trial tests if adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery can help treat stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this combination improves outcomes for patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT06730373RecruitingPhase 2
RC48, sintilimab, and S-1 for advanced HER2-positive stomach cancer
This trial tests a combination of three drugs—RC48 (a targeted therapy), sintilimab (an immunotherapy), and S-1 (a chemotherapy pill)—as a first treatment for advanced HER2-positive stomach cancer that has not been treated before. The goal is to see if this triple therapy works better than current options.
Zhengzhou, HenanAges 18–75 - NCT06008925RecruitingPhase 1/Phase 2
VG161 plus nivolumab for advanced gastric cancer
This trial tests a new combination therapy (VG161, a herpes-based virus therapy, plus nivolumab) for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two previous treatments, including a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06895447RecruitingPhase 2
Robot-assisted stomach cancer surgery after chemo or radiation
This trial tests whether using a robotic arm to remove stomach cancer is safe and effective for patients who have already received chemotherapy or radiation. If you have stage III stomach cancer and are healthy enough for surgery, this approach may offer a more precise operation.
Nanjing, JiangsuAges 18–80 - NCT06221748RecruitingPhase 2/Phase 3
Study of DV with cadonilimab for HER2-positive stomach cancer
This trial tests a combination of two drugs (DV and cadonilimab) for people with HER2-positive stomach or gastroesophageal junction cancer that has grown after first treatment. It aims to see if this combo can help when standard options have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT05620628RecruitingPhase 2
Test savolitinib plus durvalumab for MET-amplified stomach cancer
This trial studies whether blocking MET (a cancer growth signal) with savolitinib, combined with durvalumab (an immune treatment), can shrink advanced gastric (stomach) cancer that has worsened after chemotherapy. It may help people whose tumors have MET amplification and measurable disease that can be tracked on scans.
SeoulAges 19 years+ - NCT07522151RecruitingPhase 3
Adebrelimab with Surgery for Stomach Cancer
This trial tests a new immunotherapy drug called adebrelimab combined with chemotherapy and surgery for stomach cancer or junction cancers (where the stomach meets the esophagus). The goal is to see if this treatment helps prevent cancer from coming back after surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT07127822RecruitingPhase 2
Testing a new immunotherapy combo for MSI-H gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
Shijiazhuang, HebeiAges 18 years+ - NCT07069712RecruitingPhase 2
New drug combos before and after surgery for stomach or esophageal cancer
This trial is testing new drug combinations given before and after surgery for stomach or esophageal cancer that can be removed. The goal is to see if these treatments work better than standard care. You may be eligible if your tumor has certain markers and you haven't had treatment for this cancer yet.
Newark, DelawareAges 18 years+ - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT06102759Recruiting
Study of adebrelimab and fruquintinib plus chemo for advanced stomach cancer after PD-1 failure
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT07179484Recruiting
Study of CT041 for advanced stomach or junction cancer after first treatment
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
BeijingAges 18–75 - NCT07385703RecruitingPhase 3
A trial of LM-302 with tislelizumab for stomach cancer
This trial tests a new drug combination for stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if adding LM-302 to standard treatments helps people whose tumors have a specific protein called CLDN18.2.
Hefei, AnhuiAges 18 years+ - NCT06023758RecruitingPhase 2
Study of two drugs with or without chemo for HER2-positive stomach cancer
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07353684RecruitingPhase 2
Adebrelimab plus apatinib with chemo for gastric cancer
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
Beijing, Beijing MunicipalityAges 18–75 - NCT01935778RecruitingPhase 3
Extra chemo after stomach cancer surgery: compare two drug plans
This Phase 3 trial tests which combination of chemotherapy works better after surgery for stage IIIB/IV stomach or stomach–esophagus junction adenocarcinoma. Participants get randomized to one of two chemotherapy plans to see which helps people live longer and/or prevents cancer from coming back.
SeoulAges 20–75 - NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70 - NCT06830018Recruiting
New megestrol for advanced stomach or colon cancer with fatigue
This study tests a new form of megestrol (a medicine that can boost appetite and energy) for people with advanced stomach or colorectal cancer who also have fatigue and poor appetite. It is given as a first treatment, meaning you haven't had chemotherapy yet for your advanced cancer.
Shenyang, LiaoningAges 18–75 - NCT06510010RecruitingPhase 2
Chemo plus H. pylori treatment for advanced stomach cancer
This trial tests whether adding H. pylori bacteria treatment to standard chemotherapy (before and after surgery) can improve outcomes for people with locally advanced stomach cancer. It combines oxaliplatin and S-1 chemo with antibiotics to clear the infection.
GuangzhouAges 18–75 - NCT05699655RecruitingPhase 2/Phase 3
New pre-surgery treatment for advanced stomach cancer with immunotherapy
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Fuzhou, FujianAges 18–75 - NCT06627634Recruiting
Surgery for stomach cancer that spread to the liver
This trial tests if removing the stomach tumor and liver spots together can help people with stomach cancer that has spread only to the liver. It is for those who are healthy enough for surgery and chemotherapy.
Aarhus, JyllandAges 18 years+
Hear when a new Advanced Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced gastric adenocarcinoma?
- Yes. Clin2 currently lists 227 recruiting advanced gastric adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced gastric adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced gastric adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.